Coexistence of IDH1 Mutation and KIAA1549 :: BRAF Fusion in a Diffuse Glioma: A Case Report With Clinical, Radiological, and Pathological Correlation
Neuropathology · 2025
DOI: 10.1111/neup.70027 ↗Kurz gefasst
Fallbericht in der Zeitschrift Neuropathology, 2025. Verfasst von Sumanta Das und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Agilus Diagnostics Ltd., Fortis Memorial Research Institute, Gurugram, India. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Brain Neoplasms, Proto-Oncogene Proteins B-raf, Glioma. Die Arbeit nennt 34 Literaturangaben.
Abstract (Originalsprache)
Isocitrate dehydrogenase (IDH) mutations and KIAA1549::BRAF fusions are traditionally regarded as independent and mutually exclusive genetic events in gliomas. IDH mutations are hallmark features of diffuse gliomas in adults, while KIAA1549::BRAF fusions are characteristic of pediatric pilocytic astrocytomas and diffuse leptomeningeal glioneuronal tumors (DLGNTs). This report presents a rare case of a 31‐year‐old male with diffuse astrocytoma, CNS WHO Grade 4, exhibiting co‐occurrence of an IDH1 mutation (p.R132L) and KIAA1549::BRAF fusion, identified via next‐generation sequencing. Histopathology revealed a diffusely infiltrating glial tumor with high mitotic activity, endothelial proliferation, and necrosis. Immunohistochemistry supported the diagnosis, showing ATRX loss, diffuse p53 positivity, and a high Ki67 index. Molecular profiling confirmed the IDH1 mutation, TP53 mutation, CDKN2A loss, and the rare KIAA1549::BRAF fusion. Fluorescence in situ hybridization also confirmed the KIAA1549::BRAF fusion. The coexistence of these alterations challenges the conventional view of mutual exclusivity, highlighting the need for comprehensive molecular profiling in gliomas. IDH mutations lead to oncometabolite accumulation, while KIAA1549::BRAF fusion activates the MAPK pathway. This dual alteration necessitates multimodal therapeutic approaches targeting both pathways. This case emphasizes the importance of integrated diagnostics in glioma classification and personalized treatment, with further research needed to explore the implications of such rare co‐occurrences.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Agilus Diagnostics Ltd., Fortis Memorial Research Institute, Gurugram, India.
- Department of Pathology, North Eastern Indira Gandhi Regional Institute of Health & Medical Sciences, Shillong, India.
- Department of Hematology and Bone Marrow Transplant, Agilus Diagnostics, Fortis Memorial Research Institute, Gurugram, India.
- Department of Radiology, Fortis Memorial Research Institute, Gurugram, India.
- Department of Radiation Oncology, Fortis Memorial Research Institute, Gurugram, India.
- Department of Neurosurgery, Fortis Memorial Research Institute, Gurugram, India.
ORCID-Profile: Sumanta Das, Sunita Ahlawat, Shrinidhi Nathany
Zitieren
APA
Das, S., Ahlawat, S., Nathany, S., Gupta, R. K., Sharma, N., Shaikh, S., Patir, R., & Sharma, S. K. (2025). Coexistence of IDH1 Mutation and KIAA1549 :: BRAF Fusion in a Diffuse Glioma: A Case Report With Clinical, Radiological, and Pathological Correlation. Neuropathology. https://doi.org/10.1111/neup.70027
Vancouver
Das S, Ahlawat S, Nathany S, Gupta RK, Sharma N, Shaikh S, et al. Coexistence of IDH1 Mutation and KIAA1549 :: BRAF Fusion in a Diffuse Glioma: A Case Report With Clinical, Radiological, and Pathological Correlation. Neuropathology. 2025. doi:10.1111/neup.70027
BibTeX
@article{Das2025,
author = {Das, Sumanta and Ahlawat, Sunita and Nathany, Shrinidhi and Gupta, Rakesh Kumar and Sharma, Noopur and Shaikh, Salman and Patir, Rana and Sharma, Sanjeev Kumar},
title = {Coexistence of IDH1 Mutation and KIAA1549 :: BRAF Fusion in a Diffuse Glioma: A Case Report With Clinical, Radiological, and Pathological Correlation},
journal = {Neuropathology},
year = {2025},
doi = {10.1111/neup.70027}
}
EUVIMED